Administration of secretin for autism alters dopamine metabolism in the central nervous system

Brain and Development

Volumn 28, Issue 2, 2006, Pages 99-103

  Toda, Yoshihiro ^a,d   Mori, Kenji ^a   Hashimoto, Toshiaki ^b   Miyazaki, Masahito ^a   Nozaki, Satoshi ^c   Watanabe, Yasuyoshi ^c   Kuroda, Yasuhiro ^a   Kagami, Shoji ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b NARUTO UNIVERSITY OF EDUCATION   (Japan)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d TOKUSHIMA RED CROSS HOSPITAL   (Japan)

Author keywords

5HIAA; Autism; BH4; HVA; Secretin

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; DOPAMINE; HOMOVANILLIC ACID; SECRETIN; TETRAHYDROBIOPTERIN;

ARTICLE; AUTISM; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINE METABOLISM; FEMALE; HUMAN; MALE; PRESCHOOL CHILD; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE;

AUTISTIC DISORDER; BIOPTERIN; CENTRAL NERVOUS SYSTEM; CHILD; CHILD, PRESCHOOL; DOPAMINE; FEMALE; HOMOVANILLIC ACID; HORMONES; HUMANS; HYDROXYINDOLEACETIC ACID; MALE; PSYCHIATRIC STATUS RATING SCALES; SECRETIN; TIME FACTORS;

EID: 32044448767     PISSN: 03877604     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.braindev.2005.05.005     Document Type: Article

References (11)

1. M. Segawa A neurological model of infantile autism (in Japanese) No No Kagaku (Tokyo) 20 1998 169 175
2. C.J. Mcdougle, S.T. Naylor, D.J. Cohen, F.R. Volkman, G.R. Heninger, and L.H. Price A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder Arch Gen Psychiatry 53 1996 1001 1008
3. K. Horvath, G. Stefanatos, K.N. Sokolski, R. Wachtel, L. Nabros, and J.T. Tildon Improved social and language skills after secretin administration in patients with autistic spectrum disorders J Assoc Acad Minor Phys 9 1998 9 15
4. H. Naruse, T. Hayashi, M. Takesada, A. Nakane, and K. Yamazaki Metabolic changes in aromatic amino acids and monoamines in infantile autism and development of new treatment related to the finding (in Japanese) No To Hattatsu 21 1989 181 189
5. E. Fernell, Y. Watanabe, I. Adolfsson, Y. Tany, M. Bergstrom, and P. Hartvig Possible effects of tetrahydrobiopterin treatment in six children with autism - clinical and positron emission tomography data: a pilot study Dev Med Child Neurol 39 1997 313 318
6. H. Komori, T. Matsuishi, S. Yamada, Y. Yamashita, E. Ohtaki, and H. Kato Cerebrospinal fluid biopterin and biogenic amine metabolites during oral R-THBP therapy for infantile autism J Autism Dev Disord 25 1995 183 193
7. N. Blau, B. Thoy, and R.G.H. Cotton Disorder of tetrahydrobiopterin and related biogenic amines C.R. Scriver A.L. Beaudet W. Sly D. Valle B. Childs K.W. Kinzler B. Vogelstein The metabolic and molecular bases of inherited disease 2000 McGraw Hill London 1725 1776
8. A.D. Sandler, K.A. Sutton, J. DeWeese, M.A. Girardi, V. Sheppard, and J.W. Bodfish Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder N Engl J Med 341 1999 1801 1806
9. J.R. Lightdale, C. Hayer, A. Duer, C. Lind-White, S. Jenkins, and B. Siegel Effects of intravenous secretin on language and behavior of children with autism and gastrointestinal symptoms: a single-blinded, open-label pilot study Pediatrics 108 2001 E90
10. T.B. Usdin, T.I. Bonner, and E. Mezey Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions Endocrinology 135 1994 2662 2680
11. M.A. Schwarzschild, and R.E. Zigmond Secretin and vasoactive intestinal peptide activate tyrosine hydroxylase in sympathetic nerve endings J Neurosci 9 1989 160 166